Actemra poised to launch IL-6 inhibitors.
Melton
Lisa
L
Coombs
Amy
A
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000639:trends; D002626:Chemistry, Pharmaceutical / Q000379:methods; D015195:Drug Design; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D007107:Immune System; D007249:Inflammation; D051379:Mice; D000093242:Interleukin-6 Inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000093242:Interleukin-6 Inhibitors; C502936:tocilizumab